MétaCan
Menu
Back to cohort
Record W2755307004 · doi:10.1093/ofid/ofx163.899

In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)

2017· article· en· W2755307004 on OpenAlexaffabout
Andrew Walkty, Melanie Baxter, Heather J. Adam, Philippe Lagacé‐Wiens, James A. Karlowsky, George G. Zhanel

Bibliographic record

VenueOpen Forum Infectious Diseases · 2017
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInfections and bacterial resistance
Canadian institutionsUniversity of ManitobaShared Health
Fundersnot available
KeywordsStenotrophomonas maltophiliaMedicineTigecyclineCeftazidime/avibactamBroth microdilutionAntimicrobialInternal medicineMicrobiologyMoxifloxacinAntimicrobial stewardshipIntensive care medicineCeftazidimeAntibioticsPseudomonas aeruginosaAntibiotic resistanceMinimum inhibitory concentrationBiologyBacteria

Abstract

fetched live from OpenAlex

Abstract Background Stenotrophomonas maltophilia is a non-fermentative gram-negative bacillus that has emerged as an important opportunistic pathogen among hospitalized, debilitated patients. Treatment options for infections caused by this organism are limited because it is intrinsically resistant to antimicrobials from multiple different classes. The purpose of this study was to evaluate the in vitro activity of several newer antimicrobial agents (ceftazidime-avibactam [CZA], ceftolozane-tazobactam [C/T], moxifloxacin [MXF], tigecycline [TGC]) and relevant comparators [e.g., trimethoprim-sulfamethoxazole [TMP-SMX]) against a large collection of S. maltophilia clinical isolates obtained as part of an ongoing national surveillance study (CANWARD, 2011–2016). Methods From January 2011 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood (100), respiratory (100), urine (25), and wound (25) infections. Susceptibility testing was performed using broth microdilution as described by CLSI. MICs were interpreted using CLSI breakpoints, where available. Results 349 S. maltophilia clinical isolates were obtained as a part of CANWARD (86% from a respiratory source). The susceptibility profile of these isolates is presented below. Conclusion TMP-SMX continues to demonstrate excellent in-vitro activity against S. maltophilia clinical isolates. MXF and TGC may also prove useful in the treatment of infections caused by this pathogen. Disclosures G. Zhanel, Achaogen: Research relationship, Research support Astellas: Research relationship, Research support Merck Canada: Research relationship, Research support Merck USA: Research relationship, Research support Paratek Pharma: Research relationship, Research support Pharmascience: Research relationship, Research support Sunovion: Research relationship, Research support Tetraphase: Research relationship, Research support The Medicines Co.: Research relationship, Research support Zoetis: Research relationship, Research support

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.046
Threshold uncertainty score0.776

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.278
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicInfections and bacterial resistanceFrench-language works237,207